{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:04:10Z","timestamp":1774742650563,"version":"3.50.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Giant cell arteritis (GCA) is characterized by inflammation of large and medium vessels. First-line therapy for the treatment of GCA are glucocorticoids, which are effective while potential adverse effects should be considered, especially during long-term use. The aim was to investigate the incidence of glucocorticoids\u2019 adverse effects and potential predictors for them.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>138 GCA patients were retrospectively evaluated for newly developed glucocorticoid adverse effects in 2020. Potential predictors, defined as initial glucocorticoid pulse therapy, relapse of GCA and concomitant polymyalgia rheumatica as well as parameters of inflammation and endothelial dysfunction, including pulse-wave velocity and intima-media-thickness, were measured in 2012.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Potential new glucocorticoid adverse effects per patient was 1 (25th-75th 0\u20133) of which chronic kidney disease progression (29%), bone fractures (23.2%), cataracts (18.1%), dementia, and arterial hypertension (each at 12.3%) were most commonly recorded. Significant associations were found between occurrence of any relapse and new diabetes mellitus and between initial glucocorticoid pulse therapy and new dementia (all with <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05). In multivariate regression analysis, any relapse was a predictor for developing diabetes mellitus (OR 9.23 [95% CI 1.33\u201364.05], <jats:italic>p<\/jats:italic>\u2009=\u20090.025). However, no correlations were observed between endothelial dysfunction or inflammatory parameters and development of new glucocorticoid adverse effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>GCA relapses may be associated for development of diabetes mellitus potentially by increasing glucocorticoid doses. Parameters of inflammation and endothelial dysfunction are not suited predictors for glucocorticoid adverse effects.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1382946","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T04:36:28Z","timestamp":1716352588000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Association of clinical, imaging and laboratory parameters with adverse effects of glucocorticoid therapy in patients with giant cell arteritis"],"prefix":"10.3389","volume":"11","author":[{"given":"Leyla","family":"Schweiger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz","family":"Hafner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Meinitzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Brodmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Dejaco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Jud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/ICU.0b013e32833eae8b","article-title":"Diagnosis and management of giant cell arteritis: a review","volume":"21","author":"Kale","year":"2010","journal-title":"Curr Opin Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/ard.2009.111005","article-title":"Increase in age at onset of giant cell arteritis: a population-based study","volume":"69","author":"Kermani","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/art.24459","article-title":"Epidemiology of giant cell arteritis and polymyalgia rheumatica","volume":"61","author":"Gonzalez-Gay","year":"2009","journal-title":"Arthritis Rheum"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international Chapel Hill consensus conference nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"ref5","first-page":"468","article-title":"Giant cell arteritis: 2018 review","volume":"115","author":"Winkler","year":"2018","journal-title":"Mo Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2174\/1573397115666190227194014","article-title":"Giant cell arteritis (GCA): pathogenesis, clinical aspects and treatment approaches","volume":"15","author":"Ciofalo","year":"2019","journal-title":"Curr Rheumatol Rev"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia Rheumatica and Giant cell arteritis: a systematic review","volume":"315","author":"Buttgereit","year":"2016","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref9","first-page":"115","article-title":"Complications of corticosteroid therapy in presumptive temporal arteritis","volume":"11","author":"Brownstein","year":"1976","journal-title":"Can J Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/art.11388","article-title":"Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes","volume":"49","author":"Proven","year":"2003","journal-title":"Arthritis Rheum"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.55563\/clinexprheumatol\/0nd4kk","article-title":"A French cohort of patients with giant cell arteritis: glucocorticoid treatment and its associated side effects","volume":"39","author":"Perrineau","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/bjh.17388","article-title":"Glucocorticoid use and risk of first and recurrent venous thromboembolism: self-controlled case-series and cohort study","volume":"193","author":"Orsi","year":"2021","journal-title":"Br J Haematol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/ene.12774","article-title":"Patterns of anti-inflammatory drug use and risk of dementia: a matched case-control study","volume":"22","author":"Dregan","year":"2015","journal-title":"Eur J Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"101830","DOI":"10.1016\/j.berh.2023.101830","article-title":"Recent advances in the treatment of giant cell arteritis","volume":"37","author":"Springer","year":"2023","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"975","DOI":"10.55563\/clinexprheumatol\/cj4ea8","article-title":"Pros and cons of TNF inhibitors and tocilizumab in the treatment of large-vessel vasculitis","volume":"41","author":"Marvisi","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e003481","DOI":"10.1136\/rmdopen-2023-003481","article-title":"Cardiovascular diseases and their associations with lipid parameters and endothelial dysfunction in giant cell arteritis","volume":"9","author":"Jud","year":"2023","journal-title":"RMD Open"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/rheumatology\/kew273","article-title":"The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease","volume":"56","author":"Dejaco","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.cca.2007.07.006","article-title":"Reference values for plasma concentrations of asymmetrical dimethylarginine (ADMA) and other arginine metabolites in men after validation of a chromatographic method","volume":"384","author":"Meinitzer","year":"2007","journal-title":"Clin Chim Acta"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.semarthrit.2020.11.003","article-title":"Prevalence and prognostic factors for aortic dilatation in giant cell arteritis\u2014a longitudinal study","volume":"51","author":"Jud","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.atherosclerosis.2015.05.007","article-title":"The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: endorsed by the Association for Research into arterial structure and physiology (ARTERY) society","volume":"241","author":"Vlachopoulos","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1386-5056(00)00083-6","article-title":"HIS purchase projects in public hospitals of Styria, Austria","author":"Gell","year":"2000","journal-title":"Int J Med Inform"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.semarthrit.2016.05.009","article-title":"Corticosteroid-related adverse events in patients with giant cell arteritis: a claims-based analysis","volume":"46","author":"Broder","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.semarthrit.2016.10.001","article-title":"Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis","volume":"46","author":"Wilson","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1136\/annrheumdis-2014-205665","article-title":"The risk of deep venous thrombosis and pulmonary embolism in giant cell arteritis: a general population-based study","volume":"75","author":"Avi\u00f1a-Zubieta","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/acr.22429","article-title":"Incidence of giant cell arteritis and characteristics of patients: data-driven analysis of comorbidities","volume":"67","author":"Petri","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.3390\/jcm11061588","article-title":"Advances in the treatment of Giant cell arteritis","volume":"11","author":"Casta\u00f1eda","year":"2022","journal-title":"J Clin Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"148157","DOI":"10.1016\/j.brainres.2022.148157","article-title":"The effects of synthetic glucocorticoid treatment for inflammatory disease on brain structure, function, and dementia outcomes: a systematic review","volume":"1798","author":"Shorey","year":"2023","journal-title":"Brain Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.medcli.2023.04.004","article-title":"Prevalence and impact of cerebrovascular risk factors in patients with giant cell arteritis: an observational study from the Spanish national registry","volume":"161","author":"S\u00e1nchez-Chica","year":"2023","journal-title":"Med Clin (Barc)"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1002\/art.11353","article-title":"Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and\/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years","volume":"48","author":"Nuenninghoff","year":"2003","journal-title":"Arthritis Rheum"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"117521","DOI":"10.1016\/j.atherosclerosis.2024.117521","article-title":"Subclinical vascular composites predict clinical cardiovascular disease, stroke, and dementia: the multi-ethnic study of atherosclerosis (MESA)","volume":"392","author":"Hughes","year":"2024","journal-title":"Atherosclerosis"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"105680","DOI":"10.1016\/j.jbspin.2023.105680","article-title":"Glucocorticoid treatment and clinical outcomes in patients with polymyalgia rheumatica: a cohort study using routinely collected health data","volume":"91","author":"Tanaka","year":"2023","journal-title":"Joint Bone Spine"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1136\/ard.2007.074997","article-title":"Treatment with corticosteroids reduces arterial stiffness in patients with polymyalgia rheumatica as measured with pulse wave analysis","volume":"67","author":"Pieringer","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"6220","DOI":"10.1038\/s41598-021-85857-4","article-title":"Prognostic impacts of glucocorticoid treatment in patients with polymyalgia rheumatica and giant cell arteritis","volume":"11","author":"Emamifar","year":"2021","journal-title":"Sci Rep"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/eci.12227","article-title":"Endothelial function and carotid intima-media thickness in giant-cell arteritis","volume":"44","author":"Hafner","year":"2014","journal-title":"Eur J Clin Investig"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects","volume":"68","author":"Huscher","year":"2009","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1382946\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T04:36:31Z","timestamp":1716352591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1382946\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":37,"alternative-id":["10.3389\/fmed.2024.1382946"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1382946","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]},"article-number":"1382946"}}